[go: up one dir, main page]

ATE485367T1 - Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren - Google Patents

Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren

Info

Publication number
ATE485367T1
ATE485367T1 AT94921953T AT94921953T ATE485367T1 AT E485367 T1 ATE485367 T1 AT E485367T1 AT 94921953 T AT94921953 T AT 94921953T AT 94921953 T AT94921953 T AT 94921953T AT E485367 T1 ATE485367 T1 AT E485367T1
Authority
AT
Austria
Prior art keywords
cells
virust
retroviruses
titer
highly efficient
Prior art date
Application number
AT94921953T
Other languages
English (en)
Inventor
Mitchell H Finer
Margo R Roberts
Thomas J Dull
Krisztina M Zsebo
Lu Qin
Deborah A Farson
Original Assignee
Gbp Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gbp Ip Llc filed Critical Gbp Ip Llc
Application granted granted Critical
Publication of ATE485367T1 publication Critical patent/ATE485367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94921953T 1993-06-11 1994-06-10 Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren ATE485367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/076,299 US5834256A (en) 1993-06-11 1993-06-11 Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
PCT/US1994/006667 WO1994029438A1 (en) 1993-06-11 1994-06-10 Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells

Publications (1)

Publication Number Publication Date
ATE485367T1 true ATE485367T1 (de) 2010-11-15

Family

ID=22131115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94921953T ATE485367T1 (de) 1993-06-11 1994-06-10 Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren

Country Status (10)

Country Link
US (3) US5834256A (de)
EP (1) EP0710280B1 (de)
JP (1) JP4409631B2 (de)
KR (1) KR100355423B1 (de)
AT (1) ATE485367T1 (de)
CA (1) CA2164835C (de)
DE (1) DE69435316D1 (de)
NZ (1) NZ269019A (de)
SG (1) SG55158A1 (de)
WO (1) WO1994029438A1 (de)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9101680A (nl) 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
JPH08504095A (ja) * 1992-09-18 1996-05-07 カンジ，インコーポレイテッド 腫瘍抑制遺伝子を有するレトロウイルスベクターによる遺伝子療法
US6051427A (en) * 1993-06-11 2000-04-18 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6506604B2 (en) * 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
JP4303315B2 (ja) * 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
AU3635695A (en) * 1994-09-19 1996-04-09 Board Of Trustees Of The Leland Stanford Junior University Methods for genetically modifying hematopoietic stem cells
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
CA2216871A1 (en) * 1995-04-20 1996-10-24 Chiron Corporation High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
US6017754A (en) * 1995-08-24 2000-01-25 Invitrogen Corporation System for isolating and identifying eukaryotic cells transfected with genes and vectors, host cells and methods thereof
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
EP0880594B1 (de) * 1996-01-23 2002-10-23 Oxford Biomedica (UK) Limited Retroviraler vektor und dessen verwendung in gentherapie
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
WO1997030169A1 (en) * 1996-02-13 1997-08-21 Fred Hutchinson Cancer Research Center 10a1 retroviral packaging cells and uses thereof
AU2998597A (en) * 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6083763A (en) * 1996-12-31 2000-07-04 Genometrix Inc. Multiplexed molecular analysis apparatus and method
US8703480B1 (en) * 1997-03-21 2014-04-22 Enzo Therapeutics, Inc. Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells
IL131979A0 (en) * 1997-03-21 2001-03-19 Enzo Therapeutics Inc Vectors and viral vectors and packaging cell lines for propagating the same
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
ATE341621T1 (de) * 1997-10-24 2006-10-15 Invitrogen Corp Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
US7294755B1 (en) * 1997-11-14 2007-11-13 Cedars-Sinai Medical Center Genetic modification of male germ cells for generation of transgenic species and genetic therapies
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20030039967A1 (en) * 1997-12-19 2003-02-27 Kris Richard M. High throughput assay system using mass spectrometry
US20100105572A1 (en) * 1997-12-19 2010-04-29 Kris Richard M High throughput assay system
US20030096232A1 (en) * 1997-12-19 2003-05-22 Kris Richard M. High throughput assay system
AU2678999A (en) * 1998-02-13 1999-08-30 Genetrace Systems, Inc. Use of ribozymes for functionating genes
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US20060183228A1 (en) * 1998-03-24 2006-08-17 Enzo Therapeutics, Inc. Viral vectors with surface or envelope components
US7074608B1 (en) 1998-05-12 2006-07-11 E. I. Du Pont De Nemours And Company Method for the production of 1,3-propanediol by recombinant organisms comprising genes for coenzyme B12 synthesis
US6432686B1 (en) 1998-05-12 2002-08-13 E. I. Du Pont De Nemours And Company Method for the production of 1,3-propanediol by recombinant organisms comprising genes for vitamin B12 transport
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US6958226B1 (en) 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
IL127142A0 (en) * 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
CA2359747A1 (en) * 1999-02-09 2000-08-17 Lexicon Genetics Incorporated Human uncoupling proteins and polynucleotides encoding the same
AU778698B2 (en) * 1999-04-29 2004-12-16 Miltenyi Biotec B.V. & Co. KG Method and means for producing high titer, safe, recombinant lentivirus vectors
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1059357A1 (de) * 1999-06-09 2000-12-13 Universite Pierre Et Marie Curie Paris Vi Replizierende oder 'semi-replizierende' retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
EP1059356B1 (de) * 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
EP1222269A1 (de) 1999-10-12 2002-07-17 Lexicon Genetics Incorporated Menschliche ldl rezeptorfamilieproteine und polynukleinesäuren die dafür kodieren
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
US6790614B1 (en) 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
US6790667B1 (en) 2000-05-30 2004-09-14 Lexicon Genetics Incorporated Human mitochondrial proteins and polynucleotides encoding the same
US7181416B2 (en) * 2000-06-08 2007-02-20 Blackstone Corporation Multi-function transaction processing system
JP4762478B2 (ja) * 2000-07-03 2011-08-31 キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー 発現ベクター
US20040235173A1 (en) * 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20040185464A1 (en) * 2000-09-15 2004-09-23 Kris Richard M. High throughput assay system
GB0024550D0 (de) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
WO2002092134A1 (en) * 2001-05-14 2002-11-21 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
US8216585B2 (en) 2001-05-25 2012-07-10 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
JP2004537539A (ja) * 2001-06-29 2004-12-16 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ ヒトグロビン遺伝子をコードするベクターとその異常ヘモグロビン血症の治療におけるその使用
AU2002327412A1 (en) 2001-08-02 2003-02-17 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
CA2915676C (en) 2001-10-02 2017-06-06 Institut Clayton De La Recherche Restricted expression lentiviral vectors
US20030148982A1 (en) * 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
AU2003238456A1 (en) 2002-02-01 2003-09-02 Oxford Biomedica (Uk) Limited Viral vector
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
AU2003226598A1 (en) * 2002-04-26 2003-11-10 Institut Clayton De La Recherche Improved chimeric glycoproteins and pseudotyped lentiviral vectors
WO2003093417A2 (en) 2002-05-01 2003-11-13 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
US6863884B2 (en) * 2002-05-01 2005-03-08 Cell Genesys, Inc. Pseudotyped retroviral vectors
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
WO2004048583A2 (en) * 2002-11-22 2004-06-10 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
EP1636360A4 (de) * 2003-06-03 2006-11-08 Cell Genesys Inc Zusammensetzungen und verfahren zur verstärkten expression rekombinanter polypeptide von einem vektor unter verwendung einer peptidspaltstelle
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US20070037284A1 (en) * 2003-06-04 2007-02-15 Enzo Therapeutics, Inc. Vectors for expressing exogenous gene or exogenous nucleic acid sequences
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
AU2004270275B2 (en) * 2003-09-09 2010-02-18 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to HIV humans
CN102174536B (zh) * 2003-10-02 2013-02-13 克鲁塞尔荷兰公司 用于重组腺病毒的包装细胞
CA2545938A1 (en) * 2003-11-12 2005-05-26 Universite Laval High-titer retroviral packaging cells
DE602004027538D1 (de) 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
CA2574282A1 (en) 2004-07-21 2006-03-02 Dana-Farber Cancer Institute, Inc. Lentiviral vectors and uses thereof
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
KR20160028498A (ko) 2004-09-24 2016-03-11 메소블라스트, 아이엔씨. 간엽 전구세포의 증식 및/또는 생존성 증강 방법
CN102391981B (zh) 2004-09-24 2014-08-20 麦索布莱斯特公司 多能扩增间充质前体细胞子代(memp)及其应用
JP2008531581A (ja) * 2005-02-23 2008-08-14 ユーエービー リサーチ ファウンデーション アルキル−グリコシドで増強されたワクチン接種
EP2399991B1 (de) 2005-04-12 2017-09-27 Mesoblast, Inc. Isolierung von erwachsenen Stammzellen durch nicht gewebespezifische Alkali-Phosphatase
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
EP2468881A3 (de) * 2005-07-21 2012-08-15 Abbott Laboratories Mehrfache Genexpression mit sORF-Konstrukten und Verfahren mit Polyproteinen, Pro-Proteinen und Proteolyse
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
BRPI0619794B8 (pt) * 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8129187B2 (en) * 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
EP1835032A1 (de) 2006-03-14 2007-09-19 Université de Liège Selbst-inaktivierender rekombinanter lentiviraler Vektor zur Inhibierung von HIV
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
WO2007124573A1 (en) * 2006-04-28 2007-11-08 Universite Laval High-titer retroviral packaging cells
NZ576445A (en) * 2006-11-02 2012-03-30 Daniel J Capon Hybrid immunoglobulins with moving parts
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
EP2155862A2 (de) 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex-vivo-expansion menschlicher hämatopoetischer stammzellen
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CN101827603B (zh) 2007-08-06 2013-03-06 成血管细胞系统公司 用于体内生成、修复和/或维护结缔组织的方法
EP2098536A1 (de) * 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
JP5346925B2 (ja) 2008-05-02 2013-11-20 国立大学法人京都大学 核初期化方法
CN104678106B (zh) 2008-08-18 2016-12-07 中胚有限公司 单克隆抗体stro-4
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
EP2493923A1 (de) 2009-10-30 2012-09-05 Abbott Laboratories Sorf-konstrukte und multiple genexpression
GB0920775D0 (en) 2009-11-26 2010-01-13 King S College Cells
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2563907B1 (de) 2010-04-28 2019-06-19 The J. David Gladstone Institutes Verfahren zur erzeugung von kardiomyozyten
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2825639B1 (de) * 2012-03-13 2017-10-25 EMD Millipore Corporation Verwendung einer zentrifugenunterstützten infektion zur erhöhung eines virus-titers
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
AU2013296611B2 (en) 2012-08-01 2017-11-23 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
WO2014022376A2 (en) 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
EP2895191B1 (de) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury-protein, adenovirale vektoren zur codierung von brachyury-protein und deren verwendung
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
ES2888909T3 (es) 2013-01-09 2022-01-10 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas
EP3693398A1 (de) 2013-05-10 2020-08-12 Whitehead Institute for Biomedical Research In-vitro-herstellung von erythrozyten mit sortasefähigen proteinen
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
AU2016246655B2 (en) 2015-04-07 2021-07-22 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods for inducing cell division of postmitotic cells
CN108289940B (zh) 2015-08-03 2023-01-13 美国卫生和人力服务部 Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
JP7215905B2 (ja) 2016-03-18 2023-01-31 プレシゲン，インコーポレイテッド Ｖｉｉ型コラーゲン欠損症の治療のための組成物及び方法
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
EP3443001A4 (de) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Regulierte bioschaltkreissysteme
CN109804089A (zh) 2016-07-29 2019-05-24 朱诺治疗学股份有限公司 用于评估复制型病毒存在或不存在的方法
WO2018075623A1 (en) 2016-10-19 2018-04-26 The J. David Gladstone Institutes, A Testamentary Trust Etablished Under The Will Of J. David Gladst Genetically encoded cell death indicators and methods of use
IL266175B2 (en) 2016-10-24 2024-01-01 United Therapeutics Corp Enhancement of immunomodulatory properties of MSC using treprostinil
AU2017367695A1 (en) 2016-12-02 2019-06-13 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
WO2018106724A1 (en) 2016-12-05 2018-06-14 The Regents Of The University Of California Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
EP3746569A1 (de) 2018-01-31 2020-12-09 Juno Therapeutics, Inc. Verfahren zur untersuchung der präsenz oder absenz von replikationskompetenten viren
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
WO2020047467A2 (en) 2018-08-30 2020-03-05 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ascl1
WO2020205889A1 (en) 2019-04-01 2020-10-08 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
WO2021028837A1 (en) 2019-08-13 2021-02-18 Waters Technologies Corporation Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains
AU2020361533A1 (en) 2019-10-08 2022-04-28 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
SE544296C2 (en) 2020-02-06 2022-03-29 Wallenius Water Innovation Ab Cleaning arrangement for a liquid treatment system
CA3173567A1 (en) 2020-03-02 2021-09-10 Tenaya Therapeutics, Inc. Gene vector control by cardiomyocyte-expressed micrornas
MX2022010936A (es) 2020-03-05 2022-11-16 Neotx Therapeutics Ltd ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas.
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CN115836130A (zh) 2020-04-27 2023-03-21 朱诺治疗学股份有限公司 聚乙烯亚胺-脱氧核糖核酸复合物大小和活性的稳定化
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
CN112458120B (zh) * 2020-11-25 2022-04-12 云舟生物科技(广州)股份有限公司 基于莫洛尼氏鼠白血病病毒的自失活载体及其应用
MX2023014228A (es) 2021-06-08 2024-01-25 Touchlight Ip Ltd Vector lentiviral.
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
AU4307589A (en) 1988-09-15 1990-04-02 North Carolina State University Self-inactivating, replication defective, retroviral vectors and helper cells for producing the same
CA2156725A1 (en) * 1993-02-22 1994-09-01 Warren S. Pear Production of high titer helper-free retroviruses by transient transfection

Also Published As

Publication number Publication date
NZ269019A (en) 2000-03-27
DE69435316D1 (de) 2010-12-02
JPH08511169A (ja) 1996-11-26
KR960703169A (ko) 1996-06-19
US5858740A (en) 1999-01-12
EP0710280A1 (de) 1996-05-08
AU7246294A (en) 1995-01-03
CA2164835C (en) 2010-01-05
AU699660B2 (en) 1998-12-10
CA2164835A1 (en) 1994-12-22
KR100355423B1 (ko) 2003-04-03
EP0710280A4 (de) 1999-04-28
US5686279A (en) 1997-11-11
JP4409631B2 (ja) 2010-02-03
EP0710280B1 (de) 2010-10-20
WO1994029438A1 (en) 1994-12-22
SG55158A1 (en) 1998-12-21
US5834256A (en) 1998-11-10

Similar Documents

Publication Publication Date Title
ATE485367T1 (de) Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren
WO1997007225A3 (en) High efficiency retroviral packaging system
Wagner et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors
Frecha et al. Strategies for targeting lentiviral vectors
ES2337429T3 (es) Vectores lentivirales para la preparacion de composiciones inmunoterapeuticas.
AU656545B2 (en) DNA expression systems based on alphaviruses
CA2298892A1 (en) Lentiviral vectors derived from sivagm, methods for their preparation and their use for gene transfer into mammalian cells
DK1076715T3 (da) Lentivirale pakkeceller
ATE211766T1 (de) Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten
EP0512017A1 (de) Vakzine.
CN116218779A (zh) 载体生产
DK0835137T3 (da) Indkapslede celler, som danner viruspartikler
CN104039968B (zh) 非b亚型gag蛋白在慢病毒包装中的应用
CA2873473C (en) Lentiviral vectors containing an mhc class i promoter
Rossi et al. Optimization of mucosal responses after intramuscular immunization with integrase defective lentiviral vector
Kobayashi et al. Translation initiation of a bicistronic mRNA of Borna disease virus: a 16-kDa phosphoprotein is initiated at an internal start codon
Buffa et al. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1) HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice
CA2392221A1 (en) Bovine immunodeficiency virus (biv) based vectors
RU2006123079A (ru) Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы
CA2330618A1 (en) Viral chimeras comprised of caev and hiv-1 genetic elements
CN103540615B (zh) 一种表达人抗体全基因的慢病毒载体(Lentiviral Vector)及其方法
Chen et al. Transduction efficiency of pantropic retroviral vectors is controlled by the envelope plasmid to vector plasmid ratio
HUP9902585A2 (hu) Replikálódó molekulák in vivo előállítása
Federico et al. Anti-HIV viral interference induced by retroviral vectors expressing a nonproducer HIV-1 variant
CA2331440A1 (en) Amphotropic retrovirus packaging cell line, process for its production and use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties